Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
PFE Price Action
Last 7 days
3.6%
Last 30 days
3.9%
Last 90 days
-7.7%
Trailing 12 Months
-14.2%
PFE Stock Price
PFE RSI Chart
PFE Valuation
PFE Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
PFE Fundamentals
PFE Revenue
PFE Earnings
PFE Profitability
PFE Investor Care
The Good News
Pfizer (PFE) announced a dividend of $0.43 for Q2 2025, showcasing its long-standing commitment to returning value to shareholders through consistent dividend payments (TMCnet, https://www.tmcnet.com/usubmit/2025/04/23/10182101.htm). Despite current challenges, the stock is appealing to income-focused investors due to its 7.66% dividend yield and recent revenue growth in its oncology segment (Insider Monkey, https://www.insidermonkey.com/blog/is-pfizer-inc-pfe-a-cheap-nyse-stock-to-invest-in-according-to-hedge-funds-1506643/).
The Bad News
Pfizer (PFE) has halted the development of its weight loss drug danuglipron due to safety concerns, marking a significant setback for the company (Yahoo Finance, https://finance.yahoo.com/news/pharma-stock-roundup-j-js-131500764.html). Analysts have issued multiple 'Hold' ratings amid fears of patent expirations and a reduction in revenue estimates, indicating a cautious outlook for the stock (Markets Insider, https://markets.businessinsider.com/news/stocks/cantor-fitzgerald-initiates-a-hold-rating-on-pfizer-pfe-1034608424).
Revenue & Growth
Revenue Breakdown
As of: Dec 31, 2024
Pfizer Centre One
| |||||||||||||||||||
| |||||||||||||||||||
| |||||||||||||||||||
| |||||||||||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 63.2B | 0 | 0 | 0 |
| 2024 | 24.1B | 24.1B | 28.3B | 53.1B |
| 2023 | 32.7B | 33.0B | 23.9B | 24.0B |
| 2022 | 49.9B | 34.2B | 32.8B | 32.6B |
| 2021 | 46.1B | 55.1B | 68.9B | 60.9B |
| 2020 | 37.9B | 34.5B | 32.1B | 41.7B |
| 2019 | 41.0B | 40.8B | 40.2B | 40.9B |
| 2018 | 52.7B | 53.2B | 53.4B | 40.8B |
| 2017 | 52.6B | 52.3B | 52.5B | 52.5B |
| 2016 | 51.0B | 52.3B | 53.2B | 52.8B |
| 2015 | 49.1B | 48.2B | 47.9B | 48.9B |
| 2014 | 50.5B | 50.3B | 50.0B | 49.6B |
| 2013 | 52.7B | 51.7B | 51.4B | 51.6B |
| 2012 | 59.7B | 57.1B | 53.5B | 55.2B |
| 2011 | 65.1B | 64.4B | 65.1B | 61.3B |
| 2010 | 55.0B | 61.1B | 65.5B | 65.2B |
| 2009 | 47.3B | 46.2B | 45.8B | 49.3B |
| 2008 | 0 | 48.4B | 48.3B | 48.3B |
| 2007 | 0 | 0 | 0 | 48.4B |
Get all data in R, Python etc through our Historical Stock Data APIs
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
| CEO | Dr. Albert Bourla D.V.M., DVM, Ph.D. |
|---|---|
| WEBSITE | pfizer.com |
| SECTOR | Healthcare |
| INDUSTRY | Drug Manufacturers General |
| EMPLOYEES | 65535 |
